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   هداءالإ
مذدت لخنهضني من كل هبوة , وجس ندني بؼد كل ػثرة , وثندضلني بكل حنان من إيادي البيضاء التي الألى إ
  المجد !!! جس لترفؼني ػاليا ػلى مؼار يأبراثن ال 
 
من تجرع من وؤوس المر ليسليني كعرات الحب والحنان  إلىنامله لينسج لحظات سؼادتي .....ألى من كلت إ
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  بي الؼزيزأ.......
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لى من صاروني إرى هفسي وحلمي ومجدي بؼينيو ...أمن  إلىلى البسمة الدافئة ...إلى ملجئي وملاذي .....إ
  شيء ...زوجي الحبيب أي هون مثلأنا ,وبدوهم أهون أالدرب خعوة بخعوة ...مؼم 
 
  نوهة ولاءختي الح أعيب ...ال لى الللب إخر ...لألى ثوؤم روحي .....وهبفي اإ
 
المندس ضياء و  الدنخور ػلاء والمحامي بهاء  أحبائي خوتيإكلماتهم  غبقلى من تحلو الحياة بوحودهم و إ
  .....وزوخاتهم
 
  حنى الغالية  لى الزىرة التي ثفذحت لتزىر وحزين حياتي ......ظفلتيإ كعؼة من روحي....إلى
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Abstract 
Prodrugs are substances administered in an inactive form that is then metabolized in the 
body into the corresponding active drug. The rationale behind administering prodrugs is 
to optimize the drug absorption, distribution, metabolism, and excretion. Since first 
described in the 1950s, prodrugs continue to be a fertile area of research. There are a 
number of small pharmaceutical/biotech companies dedicated to use prodrugs for the 
delivery of older but problematic drugs as well as to develop broad-based prodrug 
technologies for application to new and future drugs  
Recently Drug design become increasingly relies on computer modeling techniques. In 
the past few decades computational chemistry methods have been utilized in calculating 
physicochemical and molecular properties of compounds. This tool can be used to 
design prodrugs that chemically (intramolecular processes) interconvert to their parent 
drugs without any involvement of enzyme catalysis. The release of the active drug is 
solely dependent on the rate limiting step of the intramolecular process. Based on DFT 
calculations three different atenolol prodrugs were designed, synthesized and 
characterized using FT-IR, 
1
H-NMR LC-MS and their in vitro intra-conversion to their 
parent drug, atenolol, revealed that the t1/2 was largely affected by the pH of the medium. 
For atenolol ProD 1 in vitro kinetic study demonstrated that the t1/2 was largely affected 
by the pH of the medium. The determined t1/2 values in 1N HCl, buffer pH 3, and buffer 
pH 5 were 1.66, 3.73, and 168 hours, respectively. And at pH 7.4 no intraconversion was 
observed. On the other hand, atenolol ProD 2 was found to be readily intraconverted, 
but In the case of atenolol ProD 3 no reaction was observed. 
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Chapter One: 
____________________________________________________________ 
Introduction 
1.1 Background  
Many therapeutic drugs have undesirable properties that may become 
pharmacological, pharmaceutical, or pharmacokinetic barriers in clinical drug 
application[1]. Among the various approaches to minimize these undesirable drug 
properties while retaining the desirable therapeutic activity is the development of new 
chemical entities with desirable efficacy and safety. However, this is an expensive and 
time consuming process that needs a screening of thousands of molecules for 
biological activity (Figure 1.1). So that,  it becomes much more feasible to modify and 
improve the properties of already existing drugs through exploring the prodrug 
approach[2].in order to get rid of their undesirable features and to increase their 
commercial  life cycle and patentability [3] . 
 
Figure (1.1) : The drug development funnel . 
A very good indication of the success of the prodrug approach can be obtained by 
examining the prevalence of prodrugs on the market. It might come as a surprise to 
many people that currently approximately 10% of all globally marketed medicines can 
be classified as prodrugs, and in 2008 alone, 33% of all approved small-molecular-
weight drugs were prodrugs [3, 4]. 
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Recently drug design become increasingly relies on computer modeling techniques. This 
type of modeling is often referred to as computer-aided drug design using computational 
chemistry to discover, enhance, or study drugs and related biologically active molecules 
[5], ideally the computational method should be able to predict affinity before a 
compound is synthesized and hence in theory only one  or two compounds need to be 
synthesized. These modern computational methods can be used for an intelligent design 
of innovative prodrugs. For example, mechanisms of some intramolecular processes that 
have been utilized for better understanding of enzyme catalysis have been recently 
investigated and exploited for the design of novel prodrug linkers. In this approach, no 
enzyme is needed for the catalysis of the intra conversion of a prodrug to its parent drug. 
The release of the drug from the corresponding prodrug is solely dependent on the rate 
limiting step for the intra conversion reaction [6, 7]. 
1.2 Prodrug 
During the past few decade, the pharmaceutical sciences have undergone a molecular 
revolution which greatly impacted the field of drug design and delivery in general, and 
the utilization of the prodrug approach in particular [8]. Today, drug discovery teams in 
pharmaceutical companies, big and small, are multidisciplinary, because of this, the idea 
of implementing a potential prodrug solution to a problematic drug is more likely to be 
put in to action early [9]. 
1.2.1 The prodrug concept 
The terms “pro-drug” and “pro-agent” were first used by Albert in 1958 in his article in 
Nature to signify a pharmacologically inactive chemical moiety that can be used to 
temporarily alter the physicochemical properties of a drug to increase its usefulness and 
decrease its associated toxicity. Others such as Harper also promoted the concept but 
used the term drug latentiation. The use of the term generally implies a chemical device 
by which a drug is linked to a chemical promoiety via a covalent bond [10-17]. 
 
According to the International Union of Pure and Applied Chemistry (IUPAC), the term 
prodrug is defined as “any compound that undergoes biotransformation before exhibiting 
its pharmacological effects (Figure 1.2) [18].  
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Figure 1.2: A simplified illustration of the prodrug concept. 
 
In most cases, prodrugs are simple chemical derivatives that require only one to two 
chemical or enzymatic transformation steps to yield the active parent drug. In some 
cases, a prodrug may consist of two pharmacologically active drugs that are coupled 
together in a single molecule so that each drug acts as a promoiety for the other; such 
derivatives are called co-drugs [19, 20]. 
An ideal prodrug should be non-toxic, and has optimal physicochemical properties, such 
as lipophilicity, solubility, and stability in GI tract or in its desired dosage form , it  must 
be stable in storage and resistant to degradation in different body fluids until that point 
when it reaches its site of action. Finally after reaching the specific site of action, there 
should be a quantitative release of the drug. It is important that the inactive moiety 
should be non-toxic, releases the active drug at an appropriate rate in vivo and preferably 
rapidly eliminated from the body [1, 21, 22] .  
The physicochemical properties and bioproperties of drugs that allow their formulation 
and delivery have recently been defined by the terms “drugable” or “drug-like” 
properties. Therefore, if a drug candidate does not have drugable properties while an 
appropriate prodrug of that molecule does, use of this prodrug can result in effective, 
safe, and efficient delivery of the parent drug to the systemic circulation and to the 
desired site of action [12]. 
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1.2.2 History of prodrug design 
Adrien Albert first introduced the term “pro-drug” in 1958 [10]. A few decades later, he 
apologized for having invented such an inaccurate term, because “predrug” would have 
been a more descriptive term. However, by that time, the original version was used too 
widely to be changed. Nonetheless, the prodrug concept has been invented long before 
Albert's publication. The first intentionally designed prodrug is most probably 
methenamine (or hexamine), which was introduced 1899 by Schering [12, 21, 23]. At 
the same time, Bayer introduced aspirin (acetylsalicylic acid) as a less irritating form of 
the anti-inflammatory agent sodium salicylate [23]. Many decades elapsed until Bayer 
introduced their next prodrug, the antibiotic prontosil, in 1935 [24]. In a similar way, 
Roche discovered the prodrug activity of the anti-tuberculosis drug isoniazid more than 
40 years after its introduction in 1952 [25]. 
Since the 1960s there has been an explosive increase in the use of prodrugs in drug 
discovery and development. At the  beginning of 21
st 
century, the property-based drug 
design became an essential part of the drug discovery and development process [26]. 
This can be seen in published journal articles, reviews, and patents, as well as in 
numbers of clinically studied and marketed medicines. Moreover, dozens of prodrugs are 
currently undergoing clinical trials. To emphasize the extent of the successful 
implementation of the prodrug approach, almost 15% of the 100 best-selling small-
molecular-weight drugs in 2009 were prodrugs [27]. 
1.2.3 Applications of prodrug approaches 
In both drug discovery and drug development, prodrugs have become an established tool 
for improving physicochemical, biopharmaceutical or pharmacokinetic properties of 
pharmacologically active agents that overcome barriers to a drug’s usefulness, thus the 
prodrug approach has been extensively studied amongst the drug design scientist for a 
wide range of applications. 
1.2.3.1 Pharmaceutical application  
 
The formulation of a new chemical entity with suspected therapeutic benefits requires that 
the drug be formulated into a delivery form that is chemically stable, free from taste and 
odor problems (particularly if it is for pediatric use or intended for parenteral 
administration), and the drug formulation must be relatively free of irritation on 
administration. For intravenous usage, the drug should have adequate water solubility and 
remain in solution for sufficient time to permit administration of the complete dose [13]. 
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The undesirable organoleptic properties and physicochemical problems associated with 
drug formulation can be resolved by prodrug approaches. 
1.2.3.1.1 Improvement of Taste 
 Taste is an important parameter in case of drugs administering orally. Taste masking 
becomes a prerequisite for bitter drugs to improve the patient compliance especially in the 
pediatric and geriatric population. The problem of bitter taste of drug in pediatric 
formulations is a challenge to the formulators in the present scenario. Masking the bitter 
taste of drugs is a potential tool for the improvement of patient compliance which in turn 
decides the commercial success of the product [28] 
Different approaches are commonly utilized to overcome bitter and an unpleasant taste of 
drugs. This includes reduction of drug solubility in saliva, where a balance between 
reduced solubility and bioavailability must be achieved, but these approaches were found 
to be limited and could not overcome the problem of bitterness [29]. 
Drugs or molecules interact with taste receptors on the tongue to give bitter, sweet or other 
taste sensations. So altering the ability of the drug to interact with taste receptors could 
reduce or eliminate their bitterness. This could be achieved by an appropriate modification 
of the structure and the size of a bitter compound. 
1.2.3.1.2 Enhancement of chemical stability 
A very important requirement of all drug products is that they must be chemically stable 
over a reasonable period, if a drug is chemically very unstable and the instability problem 
cannot be resolved by formulation means, it is sometimes possible to develop a prodrug 
with enhanced stability over the parent drug. This usually takes the form of chemical 
modification of the functional group responsible for the instability. 
1.2.3.2 Pharmacokinetic applications 
Drawbacks in pharmacokinetic parameters which affect the bioavailability and mean 
residence time of drug in body can be modulated by the prodrug approach. Following are 
the goals achieved by the prodrug approach. 
1.2.3.2.1 Enhancement of bioavailability (lipophilicity) 
For agents that are highly polar in nature, it is often the transport of the drug across the 
gastrointestinal mucosal cell membrane limits its absorption. Since most drugs are 
absorbed by passive diffusion, a degree of lipophilicity is necessary for efficient 
absorption through the gastrointestinal barrier. 
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Prodrugs are most frequently applied to mask polar and ionizable groups of a drug 
molecule with the aim to improve the membrane permeability and oral absorption. Two 
reasons can be attributed to the enhanced oral bioavailability of lipophilic compound : 
1. The lipophilic form of a drug has enhanced membrane /water partition coefficient as 
compared to the hydrophilic form thus favoring passive diffusion. 
2. The lipophilic prodrugs have poor solubility in gastric fluids and thus greater 
stability and absorption  [30-32]. 
 
1.2.3.2.2 Prolongation of duration of action 
Frequent dosing is required for drugs having short biological half-lives. This can be 
overcome by use of controlled release devices as well as the prodrug approach which can 
be employed for delayed and controlled drug release in systemic circulation. 
Prolonged release drugs are quite important in the treatment of psychoses because these 
patients require medication for extended periods of time and often show high patient 
noncompliance rates [32, 33]. 
1.2.4 Amide prodrug 
Amide prodrug approach can be used to enhance the stability of drugs, provide targeted 
drug delivery and to change lipophilicity of drugs like acids and acid chlorides[34] 
.Drugs that have carboxylic acid or amine group can be converted into amide prodrugs, 
generally they are used to a limited extent due to high in vivo stability. However, 
Prodrugs using facile intramolecular cyclization reactions have been exploited to get rid 
of this problem[35]. 
Amide prodrugs can be converted back to the parent drugs either by nonspecific 
amidases or specific enzymatic activation such as renal γ-glutamyltranspeptidase. 
1.2.5 Prodrug design by computation methods 
Since drug discovery and development is time and resources consuming process, there is 
an ever growing effort to apply computational power to the combined chemical and 
biological space in order to streamline drug discovery, design, development and 
optimization.  Fast expansion in computation methods have been made possible by 
advances in software and hardware computational power and sophistication, 
identification of molecular targets, and an increasing database of publicly available 
target protein structures. Different terms are being applied to this area, including 
 8 
computer-aided drug design (CADD), computational drug design, computer-aided 
molecular design (CAMD), computer-aided molecular modeling (CAMM), rational drug 
design, in silico drug design and computer-aided rational drug design. 
Computer-aided drug design is being utilized to identify active drug candidates, select 
the most likely candidates for further evaluation, and transform the biologically active 
compounds into suitable drugs by improving their physicochemical, pharmaceutical, 
ADMET/PK (pharmacokinetic) properties. Numerous compounds that were discovered 
and/or optimized using CADD methods have reached the level of clinical studies or have 
even gained US FDA approval [36-38]. 
Computational methods have accelerated discovery by reducing the number of iterations 
required and have often provided novel structures. Ideally the computational method 
should be able to predict affinity before a compound is synthesized and hence in theory 
only one compound needs to be synthesized [39, 40]. These computational methods 
considered as an effective tool that can be used for the design of innovative prodrugs for 
drugs that contain hydroxyl, phenol, or amine groups [41-44]. Nowadays, researchers 
have shifted from their way in synthesizing classical prodrugs into designing prodrugs 
for specific targeting of enzymes and transporters, thus increasing bioavailability and 
reducing toxicity, and achieving a better therapeutic drug’s profile [45]. 
 Targeted prodrugs can be divided into two kinds of approaches: the first by which a 
chemical moiety is linked to the parent active drug to selectively target an activating 
enzyme and the second by which the prodrug moiety is interconverted by intramolecular 
process to give the corresponding parent drug and a non-toxic linker without an 
involvement of enzymes [46-48]. Several prodrugs were designed by karaman's group 
such prodrugs will undergo cleavage reactions in physiological environments like 
stomach at pH 1.5, intestine at pH 6.5 or/and blood circulation at pH 7.4, with rates that 
are solely dependent on the structural features of the pharmacologically inactive linker. 
Different linkers were investigated for the design of large number of prodrugs such as 
anti-Parkinson (dopamine), anti-viral (acyclovir) and anti-malarial (atovaquone) that 
might be efficient in releasing the parent drugs in various rates that are dependent on the 
nature or the structural features of the linkers and provide new novel prodrugs that might 
have the potential to be with enhanced dissolution and membrane penetration and hence 
better bioavailability [49-51]. 
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Quantum mechanics (QM) such as ab initio, semi-empirical and Density Functional 
Theory (DFT), and Molecular Mechanics (MM) are increasingly being utilized and 
widely accepted as tools that provide structure-energy calculations for the prediction of 
potential drugs and prodrugs[52] . The ab initio molecular orbital methods (quantum 
mechanics) are based on rigorous utilization of the Schrodinger equation with a number 
of approximations. The use of this method is restricted to small systems that do not have 
more than thirty atoms due to the extreme cost of computation time. Semi-empirical 
methods are based on the Schrodinger equation with the addition of terms and 
parameters to fit experimental data and have afforded vast information for practical 
application. Calculations of molecules exceeding 50 atoms can be done using such 
methods. Density functional theory (DFT) is a quantum method used to calculate 
structures and energies for medium-sized systems of biological and pharmaceutical 
interest and is not restricted to the second row of the periodic table. Contrary to quantum 
mechanics, molecular mechanics is a mathematical approach used for the computation of 
structures, energy, dipole moment, and other physical properties, and is widely used in 
calculating many diverse biological and chemical systems [53-57]. 
 
1.3 Atenolol  
Atenolol (ATE), 4-[2-hydroxy-3-[(1-methylethyl) amino] propoxy] benzene acetamide, 
with a molecular weight of 266.3.  Figure 1.3 is a selective ß1-adrenoceptor antagonist, 
applied in the treatment of numerous cardiovascular disorders including: hypertension, 
angina, acute myocardial infarction, supraventricular tachycardia, ventricular 
tachycardia, and the symptoms of alcohol withdrawal. Atenolol does so by restricting 
certain nerve impulses, thereby controlling the rate and force of contraction, 
consequently reducing blood pressure in addition to its use in the treatment of Angina 
Pectoris.  
On the outset, atenolol actively reduces the heart rate, in turn decreasing systolic and 
diastolic blood pressures. The net effect of both the heart rate and blood pressure being 
controlled is the reduction in myocardial work and oxygen requirement which reduce 
cardiovascular stress, thereby preventing arrhythmia and anginal attacks. Atenolol is 
currently available as tablets in strengths of 25 mg, 50 mg and 100 mg and an injectable 
formulation (in a strength of 5 mg/ml) supplied in 10-ml ampoules [58] 
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Figure (1.3): Chemical structure of atenolol. 
 
1.4  Research problem  
1. Atenolol is a very hydrophilic molecule with a pKa of 9.6, so it undergoes 
ionization in the stomach and intestine thus its oral bioavailability is low due to 
inefficient absorption through membranes. The bioavailability of atenolol is 
between 45% and 55% of the given dose and is not increased by administration 
of the drug in a solution form [59-61]. 
2. On the other hand , atenolol is one of the most important medicines used for 
prevention of several types of arrhythmias in childhood,  but it is  unlicensed 
[62]. Atenolol is also indicated as a ﬁrst-step therapy for hypertension in elderly 
patients, who have difficulty in swallowing and, thus, tablets and capsules are 
frequently avoided. The ease of administration makes a liquid formulation an 
ideal dosage form for such patients [63]. As a result, extemporaneous 
compounding (off label), involves preparing an oral liquid from the pure drug 
powder, but formulations compounded from tablets and pure drug were stable 
only for less than one week [64, 65]. 
3. Furthermore, atenolol bitterness is considered as a great challenge to health 
sector when used among children and geriatrics. The main problem in oral 
administration of bitter drugs such as atenolol is incompliance by the patients; 
this can be overcome by masking the bitterness of a drug either by decreasing its 
oral solubility on ingestion or eliminating the interaction of drug particles to taste 
buds [66-68]. 
Hence, it is expected that design and synthesis of a relatively more lipophilic 
prodrugs by masking amine group of atenolol will lead to an increase in the stability 
of its aqueous solutions since it will be more resistant to heat or/oxidation when 
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standing in aqueous solutions.  In addition, it can provide the parent drug in a 
sustained release manner that might result in a better clinical outcome, more 
convenient dosing regimens and potentially less side effects [69]. 
1.5 Thesis objectives  
Only few atenolol prodrugs have been synthesized to date, and scientists still try 
to find new options to enhance atenolol bioavailability and stability as well. In 
this research we tried to utilize the prodrug approach to synthesis a new entity 
that will perform better therapeutic profile than the parent drug, atenolol .  
1.5.1 General objective 
The main goal of this thesis was to synthesize novel prodrugs for atenolol that 
possess superior drug profile over atenolol parent drug and will be able to 
liberate atenolol in a chemically driven controlled manner once the prodrug 
reaches the blood circulation. Thus, introducing an alternative treatment option to 
the medical community that may help in addressing the critical need in 
hypertension treatment. 
1.5.2 Specific Objectives 
To achieve our thesis goal, the following specific objectives have to be 
accomplished: 
1. To synthesize proposed atenolol prodrugs. 
2. To purify and characterize the proposed prodrugs using several 
purification and characterization techniques. 
3. To perform kinetic study of the interconversion of the synthesized atenolol 
prodrugs in different media 1 N HCl, buffer pH 3, buffer pH 5 and buffer 
pH 7.4.  
4. The synthesized prodrugs should be readily dissolved in physiological 
media. 
5. The synthesized prodrugs should increase the bioavailability profile of 
atenolol. 
6. The synthesized prodrugs should have moderate hydrophilic lipophilic 
balance (HLB) value. 
7. The synthesized prodrugs should be converted to atenolol in a 
programmable manner. 
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Chapter Two: 
_________________________________________________________ 
2. Literature Review 
2.1. Introduction 
The most common linkage used in prodrug design is the ester linkage since it is easy 
to be synthesized and its function groups, hydroxyl and carboxyl acid, are widely 
available in most parent active drugs [70].  Amide bond is another commonly used 
linkage in prodrug design. It is derived from amine and a carboxyl group. The amide 
bond has higher enzymatic stability than the ester bond. Several other types of 
linkers including oximes, imines, disulfide and uncleavable thioether bond have also 
been used in the prodrug design [34, 71-75]. 
Previous studies on the synthesis of atenolol prodrugs were focused on obtaining an 
ester linkage for tarnsdermal preparations only. Stability studies on these ester 
derivatives of atenolol have showed that the ester derivatives are much more stable 
than the corresponding alcohol, atenolol, when they are formulated in aqueous 
solutions [66, 76]. The only atenolol prodrug intended to be used for oral dosage 
form was atenolol aspirinate prodrug (aspirinm). It was described as antihypertensive 
therapy to  reduce cardiovascular death, stroke, and myocardial infarction (MI), but 
studies  showed that the coupling of atenolol and acetyl salicylic acid by means of an 
ester linkage did not produce good pharmacological results, neither in vitro nor in 
vivo [77]. 
2.2 Bioavailability 
Atenolol is a water-soluble, ionizable drug and suffers from poor bioavailability 
when given by oral route due to its incomplete intestinal absorption and first-pass 
metabolism. Being a BCS class III drug, atenolol has a low log P (0.23) value, which 
also may be the reason for its poor intestinal absorption [78]. 
The combined effect of iontophoresis and esterification techniques was investigated 
by Anroop and coworkers by conducting a study on the transdermal delivery of a 
series of atenolol ester prodrugs. A number of ester prodrugs were synthesized, 
characterized and studied for physicochemical properties and stability. An evaluation 
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of the physicochemical parameters of the ester prodrugs showed significant increase 
in lipophilicity and slight reduction in the pKa value compared to that of the parent 
drug. In the prodrug series, permeation rate increased with an increase in the length 
of alkyl side chain up to the addition of 5 carbon units, but thereafter no specific 
pattern was recorded [66]. 
2.3 Stability 
Since Atenolol is unstable in solutions and are not formulated for easy or accurate 
administration to children and elderly patients, the development of a liquid dosage 
form is a significant challenge. Several studies showed that the degradation rate of 
atenolol is dependent on the temperature, indicating higher stability at 4 
o
C. Atenolol 
syrup is stable for 9 days, with acceptable appearance [64].  
 
Stability of atenolol in extemporaneously compounded liquid formulations was also 
studied in various vehicles. Atenolol powder or tablets was prepared at a 
concentration of 2 mg/ml in vehicles of Ora-Sweet, Ora-Sweet SF and Ora-Plus; as 
well as Roxane®: diluent consisting of 1% ethanol, 0.05% saccharin in a cherry-
flavored, 33% polyethylene glycol 8000 and purified water. Atenolol was found to 
be not stable in Ora-Sweet. The authors recommend atenolol in Ora-Sweet SF as the 
vehicle where it was most stable for at least 90 days or in the Roxane Diluent where 
it was stable for up to 40 days [79]. 
Another study was conducted by Patel and coworkers by using simple syrup, a 
methylcellulose-based vehicle, Ora-Sweet, Ora-Plus, and Ora-Sweet SF vehicles. 
The concentration of atenolol in the formulations was 2 mg/mL. The HPLC results 
showed that all formulations prepared using the methylcellulose-based vehicle and 
Ora-Sweet SF were stable (ie, greater than 90% of atenolol remained unchanged) for 
more than 28 days. On the other hand, formulations prepared with simple syrup and 
Ora-Sweet were stable only for 14 days [65]. 
On the other hand, in a research study that was conducted by krzek to investigate the 
relationship between the polarity of atenolol, acebutolol, and propranolol described 
by their log P values and kinetic and thermodynamic parameters characterizing their 
degradation process in acidic solution. it has been found that the stability of drugs 
increases toward lipophilic propranolol in the assumed experimental model. The 
stability was found to be increased from the most hydrophilic atenolol, through 
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acebutolol, of lower polarity, to the most lipophilic propranolol. This study 
demonstrated that the stability of the chosen beta-adrenergic blocking agents 
increases with their lipophilicity [80]. 
2.4  Masking a bitter sensation 
Many taste masking approaches have been used to improve the taste of strongly bad 
tasting medications and enhance the patient compliance. Among the approaches used 
to mask bitter taste of pharmaceuticals are: (1) taste masking using flavors, 
sweeteners and amino acids, (2) taste masking with lipophilic vehicle, (3) coating 
which is one of the most efficient and commonly used taste masking technique,  (4) 
microencapsulation is a technique applicable to protect materials from oxidation, 
volatilizing as well as to mask their bitter tastes, (5) taste suppressants which are 
used for masking bitter taste of various compounding by competing on binding to the 
G-protein coupled receptor sites, (6) ion exchange resins, (7) inclusion complexes in 
which the drug molecule fits into the cavity of a complexing agent forming a stable 
complex, (8) pH modifiers, (9) adsorbates, (10) chemicals; the solubility and 
absorption of drugs can be modified by the formation of molecular complexes, (11) 
solid dispersions, (12) multiple emulsions, (13) liposomes and (14) prodrugs. 
The problem of the bitter taste of drugs in pediatric and geriatric formulations still 
creates a serious challenge to pharmacists. Thus, different strategies should be 
developed in order to overcome this serious problem. The novel chemical approach 
utilized  in this research  involves the design of prodrugs for masking the bitter taste 
of pharmaceuticals based on intramolecular processes using density functional theory 
(DFT) and ab initio calculation methods and correlations of experimental and 
calculated reactions rates supposed by professor Karaman [81]. For example, 
paracetamol, a widely used pain killer and fever reducer found in the urine of 
patients who had taken phenacetin, has a very unpleasant bitter taste [82]. 
Phenacetin, on the other hand, lacks or has very slight bitterness. The difference in 
the structural features of both drugs is only in the nature of the group in 
the para position of the benzene ring. While in the case of paracetamol the group is 
hydroxyl, in phenacetin, it is ethoxy. Acetanilide has a chemical structure similar to 
that of paracetamol and phenacetin but lacks the group in the para position of the 
benzene ring, making it lacks the bitter taste characteristics of paracetamol  (Figure 
2.1 ).  
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These combined facts suggest that the presence of the hydroxy group on 
the para position is the major contributor for the bitter taste of paracetamol. It is 
believed that paracetamol interacts with the bitter taste receptors via hydrogen 
bonding which involves its phenolic group. In fact, recent study published by 
professor Karaman on binding of paracetamol and its prodrugs to bitter taste 
receptors has confirmed that prodrugs lacking the hydroxyl group are not bitter. 
Similarly, it is expected that blocking the amine group in atenolol with a suitable 
linker might inhibit the interactions between the amine group in atenolol and its 
bitter taste receptor/s and hence mask its bitterness. 
 The nature of the bitter taste activation with either paracetamol (via the phenolic 
group) or atenolol (via the amine group) is likely to be as a result of hydrogen 
bonding between the substrate (drug) and its receptor/s [83].  
 
 
 
 
Figure 2.1: Chemical structures of paracetamol, phenacetin and acetanilide. 
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Chapter Three: 
_________________________________________________________ 
3. Experimental Part 
 
This chapter consists of two parts. The first one concerns with the reagents, instruments 
and reactions involved in atenolol ProD 1, ProD 2 and ProD 3 synthesis. The second 
one is the Kinetic studies part which describes the specific preparations and analysis 
used to investigate atenolol prodrugs hydrolysis in different pH solutions using an HPLC 
instrument. 
1.1 Part one 
1.1.1 Materials and Instrumentation 
1.1.1.1 Materials: 
 
Pure atenolol standard was commercially available, maleic anhydride, 2,3-dimethyl 
maleic anhydride, 2,2-dimethyl succinic anhydride, anhydrous sodium dihydrogen 
phosphate, sodium hydroxide, concentrated hydrochloric acid and magnesium sulfate 
anhydrous were commercially obtained from sigma Aldrich. HPLC grade solvents of 
methanol, acetonitrile and water were purchased from Sigma Aldrich. High purity 
chloroform, DMF and diethyl ether (> 99%) were purchased from Biolab . 
1.1.1.2 Instrumentation 
The melting points were determined in open capillaries on electrothermal stuart SMP3 
advanced melting point apparatus, IR spectra were obtained from a KBr matrix (4000–
400 cm
-1
) using a Perkin-Elmer Precisely, Spectrum 100, FT-IR spectrometer. 
The LC/ESI-MS/MS system used was Agilent 1200 series liquid chromatography 
coupled with a 6520 accurate mass quadruple-time of flight mass spectrometer (Q-TOF 
LC/MS). The analysis was performed in the positive electrospray ionization mode. The 
capillary voltage was 4.0 kV, the scanned mass range was 200-540 m/z (MS). The high 
pressure liquid chromatography (HPLC) system consisted of an Alliance 2695 module 
equipped with 2996 Photodiode array detector from Waters (Germany). Data acquisition 
and control were carried out using Empower 2 ™ software (Waters, Germany). Analytes 
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were separated on a 4.6 mm x 150 mm XBridge® C18 column (5 μm particle size) used 
in conjunction with a 4.6 x 20 mm, XBridge® C18 guard column. Microfilters of 0.45 
μm porosity were normally used (Acrodisc® GHP, Waters).  
pH values were recorded on pH meter model HM-30G: TOA electronics ™ was used in 
this study to measure the pH value for each sample, thin-layer chromatography (TLC) 
was carried out on TLC plastic sheets silica gel, 20 X 20 cm, layer thickness 0.2 mm, the 
spots on the chromatograms were localized by UV light. 
UV-Spectrophotometer: the concentrations of samples were determined 
spectrophotometrically (UV-spectrophotometer, Model: UV-1601, Shimadzu, Japan) by 
monitoring the absorbance at λmax for each drug. Centrifuge: Labofuge
®
200 Centrifuge 
was used, 230 V 50/60 Hz. CAT. No.  284811. Made in Germany. 
1
H-NMR: Data were 
collected using Varian Unity Inova 500 MHz spectrometer equipped with a 5-mm 
switchable and data were processed using the VNMR software. For 
1
H-NMR, chemical 
shifts are reported in parts per million (ppm, δ) downfield from tetramethylsilane (TMS). 
Spin multiplicities are described as s (singlet), brs (broad singlet), t (triplet), q (quartet), 
and m (multiplet).  
1.1.2 Chemical synthesis of atenolol Prodrugs  
Synthesis of the atenolol prodrugs was accomplished using Kirby’s procedure [84]. 
(Scheme 1); in a 250 ml round bottom flask equipped with a stirrer and a condenser, 2.66 
gm of standard atenolol (10 mmol)  was dissolved in DMF  (100 ml), then 1 equivalent 
maleic anhydride ( 0.98 gm (10 mmol )), 2,3-dimethyl maleic anhydride (1.26 gm (10 
mmol)) or 2,2-dimethyl succinic anhydride (1.28 gm (10 mmol))  was added, the 
reaction mixture was refluxed for four hours, cooled, the DMF was removed by 
evaporation, the resulting residue was dissolved in 20 ml 1 N NaOH, extracted with 3 x 
30 ml of ether, the organic layer was dried over MgSO4 anhydrous and the dry residue 
was crystallized. 
Reaction of atenolol with maleic anhydride provided atenolol ProD 1 (2.95 gm) with  
yield of 81% , it was a white precipitate with M.P. of 185 
o
C, while reaction of atenolol 
with 2,3-dimethyl maleic anhydride provided atenolol ProD 2 (2.75 gm) with  yield of 
70% , it was a white precipitate with M.P. of 205 
o
C, finally , reaction of atenolol with 
2,3-dimethyl maleic anhydride provided atenolol ProD 3 (3.03 gm) with  yield of 77% , 
it was a yellowish greasy product . 
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Scheme 1: Synthetic schemes for the preparation of (a) atenolol ProD 1, (b) atenolol 
ProD 2 and (c)  atenolol ProD 3  from atenolol and the corresponding anhydride. 
 
1.2 Part two 
1.2.1 Determination of the partition coefficient 
The partition coefficients (log P) were determined at room temperature with an organic 
phase (1- octanol)/aqueous phase (water). Before use, 1-octanol was saturated with water 
by stirring vigorously for 24 h. A known concentration of each compound was dissolved 
in water. The solution was shaken with a suitable volume of 1- octanol for 60 minutes 
.After shaking; the phases were separated by centrifugation at 10000 rpm for 10 minutes. 
The concentrations of the compounds in the water phase before and after the partitioning 
were determined by UV-visible spectrophotometer.  
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1.2.2 Kinetic studies on the stability of atenolol prodrugs at different buffer media 
In this part, the conversion time of atenolol ProD 1, ProD 2 and ProD 3 into their parent 
drug in aqueous media were evaluated. This was accomplished by evaluating chemical 
hydrolysis of the prodrugs at pH 1, 3, 5 and 7.4 solutions which corresponding to 
different physiological media within the human body. 
In order to determine the hydrolytic rate of the prodrugs at different pH media, certain 
preparations were performed as follows. 
3.2.1.1 Buffer preparation 
potassium dihydrogen phosphate (6.8 g ) were dissolved in 900 ml water for HPLC, the 
pH of buffers pH 2 and pH 3 was adjusted by diluted o-phosphoric acid and water was 
added to a final volume of 1000 ml (0.05M). The same procedure was done for the 
preparation of buffers pH 5 and 7.4, however, the required pH was adjusted using 1 N 
NaOH [85]. 
3.2.1.2 Calibration curve for atenolol and atenolol Prodrugs 
To construct a calibration curve for atenolol prodrugs and the parent drug, atenolol, 
several concentrations (10, 50, 100, 200, 300 and 500 ppm) were prepared. All samples 
were injected into HPLC-PDA. The optimal HPLC conditions used for the analysis of 
atenolol: 4.6 mm x 150 mm, 5 μm, XBridge ® C18 column, a mixture of buffer (pH 
3.4):acetonitrile (85:15 v/v) as a mobile phase, a flow rate of 0.5 ml/minute and a UV 
detection at a wavelength of 230 nm. Peak area vs. concentration of the atenolol and 
atenolol prodrugs (ppm) was then plotted, and R
2
 value of the plot was recorded. 
3.2.1.3 Preparation of standard atenolol and atenolol prodrugs solutions. 
A 500 ppm of standard atenolol was prepared by dissolving 50 mg of atenolol in 100 ml 
of 1N HCl, buffer pH 3, buffer pH 5 or buffer pH 7.4, and then each sample was injected 
into HPLC to detect the retention time of atenolol. 
A 500 ppm of standard linker (maleic anhydride, 2,3-dimethyl maleic anhydride and 2,2-
dimethyl succinic anhydride) was prepared by dissolving 50 mg of each linker in 100 ml 
of 1N HCl, buffer pH 3, buffer pH 5 or buffer pH 7.4, then each sample was injected into 
HPLC to determine the retention time for the linker. 
A 500 ppm of atenolol ProD 1-3 was prepared by dissolving 50 mg of the atenolol  
ProD 1-3  in 100 ml of 1N HCl, buffer pH 3, buffer pH 5 or buffer pH 7.4 then each 
sample was injected into the HPLC to determine the retention time. 
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The progression of reaction was followed by monitoring the disappearance of the 
prodrug and appearance of atenolol and linker with time. 
3.2.2 Hydrolysis of atenolol Prodrugs 
Atenolol ProD 1-3 rate hydrolysis was studied at 37 
o
C in buffer solutions at different 
pHs (1N HCl, pH 3, pH 5 and pH 7.4); samples of the reaction mixtures were analyzed 
directly by HPLC, quantitative analysis of atenolol prodrugs and their hydrolysis 
product, atenolol, was obtained using a calibration curve. 
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Chapter 4: 
__________________________________________________________ 
4. Results and discussion 
4.1 Introduction: 
Atenolol ProD 1-3 were successfully synthesized, characterized and kinetically studied 
in different buffers with pH values corresponding to different physiological media inside 
the body. 
As shown in Figure 4.1, the atenolol prodrugs have a carboxylic acid group (hydrophilic 
moiety) and a lipophilic moiety (the rest of the molecule), where the combination of both 
groups ensures a moderate HLB. It should be noted that the HLB value of the prodrug 
moiety will be determined upon the physiologic environment by which the prodrug is 
dissolved in. For example, in the stomach, the atenolol prodrugs will primarily exist in 
the carboxylic acid form whereas in the blood circulation the carboxylate anion form 
will be predominant.  
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Figure 4.1: Acid-catalyzed hydrolysis for atenolol ProD 1-3  
 
4.2 Results   
4.2.1 Chemical synthesis: 
Synthesis of the atenolol ProD 1-3 were accomplished using Kirby’s procedure [84]. 
The scheme demonstrates a conjugation reaction in which a nucleophilic attack (SN2 
reaction) takes place between the NH group of atenolol  and the electrophile center of 
(maleic anhydride, 2,3-dimethyl maleic anhydride and 2,2-dimethyl succinic anhydride). 
This attack results in ring opening of (maleic anhydride, 2,3-dimethyl maleic anhydride 
and 2,2-dimethyl succinic anhydride) and the formation of an amide in the given 
prodrug, which is supposed to be cleaved once is exposed to a physiological 
environment within the body.  Moreover, 1 N NaOH was added to dissolve the final 
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product in order to obtain sodium carboxylate salt since this form is expected to be stable 
in aqueous medium . 
 
 
 
Scheme 1: Synthetic schemes for the preparation of (a) atenolol ProD 1 , (b) atenolol 
ProD 2 and (c)  atenolol ProD 3 from its parent drug, atenolol. 
 
Reaction of atenolol with maleic anhydride, 2,3-dimethyl maleic anhydride or 2,2-
dimethyl succinic anhydride provided atenolol ProD 1, ProD 2 and  ProD 3, 
respectively  with  yields of 81% , 70% and 77%,  M.P. for  ProD 1 and ProD 2 were 
185 
o
C, 205 
o
C respectively and ProD 3 provide yellowish greasy product (table 4.1 ). 
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Table 4.1: results of atenolol prodrugs chemical synthesis in the lab  
Prodrug Weight of product Melting point Appearance of product %  of yield 
ProD 1 2.95 g 185 
o
C White precipitate 81% 
ProD 2 2.75 g 205 
o
C White precipitate 70% 
ProD 3 3.03 g  - yellowish greasy product 77% 
 
 Atenolol ProD 1 ,1H-NMR δ (ppm) CD3OD 1.06 (q, 2H, J =7 Hz, CH-CH2-
CH2), 1.40 (q, 2H, J =7 Hz, CH-CH2-CH2), 1.54 (m, 1H, CH2-CH-CH2-CH2), 
1.84 (m, 2H, CH2-CH2-CH ), 2.02 (m, 2H, CH2-CH2-CH), 2.22 (m, 1H, CH2-
CH-CH2-CH2), 3.17 (d, 2H, J=6.5 Hz, CH2-N), 6.25 (d, 1H, J = 14 Hz, 
HC=CH), 6.45 (d, 1H, J = 14 Hz, HC=CH). IR (KBr/νmax cm
–1
) 1712 (C=O), 
1643 (C=O), 1587 (C=C), 1420, 1280, 1200, 1132, 1058.LC-MS m/z 365 
(M+1)
+
. 
 Atenolol ProD 2, this prodrug was unstable and readily cleaved to its parent 
drug, atenolol. 
 Atenolol ProD 3 , 1H-NMR δ (ppm) CD3OD 1.26(d,6H) , 2.99( s,6H) , 
3.28(s,2H), 3.45(s,2H) , 3.96 (m , 2H), 4.10 (m, 1H), 4,23( m,1H), 4.3(m, 2H), 
6.92 (m , 2H) , 7.22 (m , 2H).   
 
4.2.2 Characterizations: 
Atenolol and atenolol prodrugs were characterized by TLC, melting point, partition 
coefficient, HPLC, FT-IR, LC_MS and H-NMR spectroscopy. 
4.2.2.1 Thin layer chromatography: 
 TLC was performed continually as the fractions were obtained, to ensure product 
elution. Mobile phase was chloroform: methanol (50%:50%), TLC shows that a pure 
product was obtained, prodrugs shows the highest retention time values which indicate 
that they are more lipophilic than atenolol and linkers. 
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4.2.2.2 Melting point: 
 
The melting point was performed for both atenolol and the proposed atenolol prodrugs 
as a preliminary analysis of the material, melting point was determined by using SMP3 
advanced melting point apparatus.  
It was given that the melting point of atenolol was 145 ᵒ C, while that for atenolol ProD 
1 and ProD 2 were 185 
o
C, 205 
o
C respectively. ProD 3 provide a yellowish greasy 
product .  As shown, products melting points were different from that of atenolol. This 
gives a preliminary indication that these compounds are not atenolol. 
4.2.2.3 Water partition (log P) 
Lipophilicity refers to the ability of the drug molecule to partition between two 
immiscible solutions, such as water and lipid like solutions (as 1- octanol). In a similar 
manner to solubility, lipophilicity is the sum of different physicochemical characteristics, 
such as molecular weight, intra and intermolecular H- bonding, polar surface area, ionic 
charge, pKa and counter ion [86]. 
Lipophilicity increases with the elevation in the molecular weight and decreases with the 
increase of H- bonding capacity and polar surface area [87]. Also lipophilicity, again 
similar to solubility, is dependent on the pH in an inverse manner; ionization of the 
compound usually leads to decreased lipophilicity. Lipophilicity of drug molecules is 
most often estimated by 1- octanol/water partition (log P) and distribution (log D) 
coefficients. The term log P is used when all the solute is in the neutral state and the log 
D is used when pH causes part or all of the solute to be ionized. To achieve sufficient 
membrane permeation by a passive transcellular mechanism, the log D values are 
generally between 0-3 and molecular weight < 550. On the other hand, good permeation 
of the drug molecule with a negative log P value points to the involvement of carrier 
mediated transport [87]. 
 log p values of atenolol ProD 1-3 were estimated by 1- octanol/water partition, they 
were 0.44, 0.48, 0.51 respectively, while it is 0.23 for atenolol, this means that that the 
prodrugs have significant increase in lipophilicity over their parent drug, atenolol.  
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4.2.2.4 FT-IR Analysis:  
 
The following figures show the FT-IR spectra of atenolol ,  atenolol ProD 1 and atenolol 
ProD 3. The spectrum of the prodrug shows that an aliphatic stretching of C=O group at 
1712 is present, which is most likely an indication of the presence of the carbonyl group 
of the maleic  linker, in addition to the presence of signals of common groups in both the 
parent drug and the prodrug. 
 
Figure 4.2: FT-IR spectrum of atenolol. 
Table 4.2:  FT-IR spectrum analysis of atenolol. 
IR frequency band (cm
-1
) Group responsible 
3368 -OH 
3198-3071 H-N 
2966 C-CH3 
2924 CH2 
2870 C-H 
1666 C=O 
1649 O=C-NH2 
1614 Conjugated C=C (aromatic) 
886 C=CH2 
 30 
 
Figure 4.3: FT-IR spectrum of atenolol ProD 1. 
 
The IR spectrum (Figure 4.3) shows an additional signals with absorbance 1712 cm-1, 1643 cm-1 
corresponds to C=O of the maleate moiety (Table 4.2 )  . 
 
Table 4.3 :  FT-IR spectrum analysis of atenolol prodrug . 
IR frequency band (cm
-1
) Group responsible 
1712 C=O 
1643 second (C=O) 
1587 (C=C) 
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Figure 4.4: Zoomed FT-IR spectrum of atenolol ProD 3. 
 
The zoomed  IR spectrum (Figure 4.4) shows an additional signals with absorbance 1790 cm-
1
,corresponds to carbonyl group (C=O)  of the dimethyl succinate moiety   . 
 
4.2.2.5 1H-NMR of atenolol and atenolol proD 1 and proD 3 
The following figures show the H-NMR results of atenolol and atenolol ProD 1 and 
ProD 3, respectively.  
 
a. Atenolol ProD 1,  1H NMR δ (ppm) (500  MHz, MeOD) 1.16–1.23 (d, 
6H, CH3CHCH3), 3.45–3.47 (d, 2H, J = 1.4  Hz, NH2-CO-CH2–), 3.49-3.50 
(m, 2H, N–CH2–) 3.52–3.55 (m, 1H, –NCH(CH3)2), 4.00-4.01 (m, 1H, 
CH2CH(OH)CH2), 4.24–4.27 (m, 1H, –O–CH2–), 4.41–4.43 (m, 1H, –OCH2–
), 5.96 (s, 2H, –NH2), 6.04–6.07 (d, 1H, J = 13.3  Hz, –CH=CH–), 6.28–6.32 
(d, 1H, J = 13.3  Hz, –CH=CH–), 6.88–6.93 (m, 2H, aromatic), 7.18–7.22 
(m, 2H, aromatic). 
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Figure 4.5: Chemical structure of atenolol ProD 1. 
 
 
 
Figure 4.6: Atenolol 
1
 HNMR spectrum. 
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Figure 4.7 a :
1
 H-NMR of atenolol ProD 1. 
 
Figure 4.7 b :
1
 H-NMR of atenolol ProD 1; with zooming. 
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Figure 4.7 c:
 1
 H-NMR of atenolol ProD 1; with zooming. 
 
b. Atenolol ProD 3 , 1H-NMR δ (ppm) CD3OD 1.26(d,6H) , 2.99( s,6H) , 
3.28(s,2H), 3.45(s,2H) , 3.96 (m , 2H), 4.10 (m, 1H), 4,23( m,1H), 4.3(m, 
2H), 6.92 (m , 2H) , 7.22 (m , 2H).   
 
  
 
 
 
 
 
Figure 4.8: Chemical structure of atenolol ProD 3. 
 
 35 
 
Figure 4.9 a:
1
 H-NMR of atenolol ProD 3. 
 
Figure 4.9 b: 1 H-NMR of atenolol ProD 3; with zooming. 
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Figure 4.9 c :
1
 H-NMR of atenolol ProD 3; with zooming. 
 
4.2.2.6 LC/MS spectrum of atenolol Prodrugs 
 
a. Atenolol ProD 1  : A high resolution LC-MS (Figure 4.10) shows a protonated 
peak at m/z 365.1705(m+1)
 + 
which is the molecular weight of the purposed 
atenolol ProD 1 
 
 
Figure 4.10 : LC- MS spectrum of atenolol ProD 1. 
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b. Atenolol ProD 3 : A high resolution LC-MS (Figure 4.11) shows a protonated 
peak at m/z 365.1705(m+1)
 + 
which is the molecular weight of the purposed 
atenolol ProD 3. 
 
 
Figure 4.11 : LC- MS spectrum of atenolol ProD 3. 
 
4.3.7 Atenolol ProD 2 : 
Atenolol ProD 2 was unstable and readily cleaved after few hours of synthesis, Figure 
4.12 shows a rapid hydrolysis of atenolol ProD 2 after 3 hours of synthesis. Therefore,  
no H-NMR spectroscopy and LC/MS spectrum was obtained for this prodrug. 
 
 
 
 
 
 
 
Figure 4.12: Chromatograms showing the intra-conversion of atenolol ProD 2 (a) at zero 
time and (b) after 3 hours of synthesis. 
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4.2.3 Kinetic study:  
4.2.3.1 Calibration curve  
In order to follow the hydrolysis rate of the synthesized atenolol prodrugs, a 
calibration curve was obtained by plotting the HPLC peak area of atenolol Prodrugs 
versus different concentrations, as displayed in Figures 4.13 and 4.14. Excellent 
linearity with correlation coefficient (R
2
) of 0.9996 was obtained. Quantitative 
analysis of the prodrug and its hydrolysis products was achieved by using a 
calibration curve under same conditions. 
 
y = 0.0179x - 0.0124
R² = 0.9996
0
2
4
6
8
10
0 100 200 300 400 500 600
ar
e
a 
conc. (ppm)
Calibration Curve of Atenolol ProD 1 
 
Figure 4.13: Calibration curve for atenolol ProD 1. 
 
Figure 4.14: Calibration curve for atenolol ProD 3. 
4.2.3.2 Hydrolysis studies: 
The kinetics of the acid-catalyzed hydrolysis study for atenolol prodrugs were carried 
out in aqueous buffers in a similar manner to that done by Kirby on N-alkylmaleamic 
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acids [88] . This is in order to examine whether atenolol prodrugs are hydrolyzed in 
aqueous medium and to what extent. Acid-catalyzed hydrolysis of atenolol prodrugs 
were investigated in four different aqueous media: 1 N HCl and buffers pH 3, 5 and 7.4. 
Under the experimental conditions, atenolol ProD 1 was hydrolyzed to release the parent 
drug atenolol as shown by HPLC. At constant pH and temperature, the reaction 
displayed strict first order kinetics as the kobs was fairly constant and a straight line was 
obtained on plotting log concentration of residual atenolol prodrug verses time. 
4.2.3.2.1 Atenolol ProD1 hydrolysis at pH 1 
 
 
 
 
 
Figure 4.15: First order hydrolysis of atenolol ProD1 at pH 1. 
            
Figure 4.16: Chromatograms showing the intra-conversion of atenolol ProD 1 in 1N HCl 
(a) at zero time, (b) at the end of reaction. 
 
4.2.3.2.2 Atenolol ProD1 hydrolysis at pH 3 
 
a b 
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Figure 4.17:  First order hydrolysis of atenolol ProD 1 at pH 3. 
 
 
 
       
 
 
Figure 4.18: Chromatograms showing the intra-conversion of atenolol ProD 1 at pH 3 
(a) at zero time, (b) after 2 hours and (c) at the end of reaction. 
 
 
 
4.2.3.2.3 Atenolol ProD1 hydrolysis at pH 5 
a b 
c 
 41 
 
 
 
 
 
 
 
 
 
Figure 4.19 : First order hydrolysis of atenolol ProD 1 at pH 5. 
 
 
Figure 4.20 :  Chromatograms showing the intra-conversion of atenolol ProD 1 at pH 5 
(a) at zero time and (b) after 250 hours. 
 
 
 
 
4.2.3.2.4 Atenolol prodrug hydrolysis at pH 7.4. 
No change in the atenolol prodrug was observed by the HPLC results, it was extremely 
stable (Figure 4.21 ). 
a b 
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Figure 4.21:  Chromatogram showing the stability of  atenolol ProD 1 at pH 7.4 after 10 
days.  
 
4.2 Discussion 
4.2.1 Design of atenolol prodrugs based on DFT calculations of the acid-
catalyzed hydrolysis of N-alkyl maleamic acids. 
Figure 2.2 illustrates the chemical structures of two atenolol prodrugs that were 
designed by Karaman’s group. The only difference between the proposed atenolol 
prodrugs and the parent drug, atenolol, is that the amine group in atenolol was 
replaced with an amide moiety. This chemical change is expected to increase the 
stability of the prodrug derivative (amide alcohol) which is formed compared to the 
corresponding amine alcohol, atenolol, due to general chemical stability for secondary 
alcohols over amine alcohols. 
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Figure 4.22 : Chemical structures for atenolol prodrugs ProD 1-2 
The proposed atenolol prodrugs were designed based on the findings that emerged 
from the study of the acid -catalyzed hydrolysis reactions of N-alkyl maleamic acids 
conducted by Kirby et al. (Figure 2.3) [87]. Figure 2.4 depicts the acid-catalyzed 
hydrolysis reactions of N-alkyl maleamic acids studied by Kirby and Lancaster. This 
study findings demonstrate that the amide bond cleavage is due to intramolecular 
nucleophilic catalysis by the adjacent carboxylic acid group and the rate-limiting step 
of the process is the dissociation of the tetrahedral intermediate (Figure 2.5). Two 
decades later, the reaction was theoretically investigated by Katagi using AM1 
semiempirical calculations. In contrast to what was proposed by Kirby, the AM1 
study revealed that the rate-limiting step is the tetrahedral intermediate formation and 
not its collapse [89, 90]. Later on, Kluger and Chin have studied the intramolecular 
hydrolysis mechanism of a number of N-alkylmaleamic acids derived from aliphatic 
amines having a wide range of basicity [91]. Their findings revealed that the identity 
of the rate-limiting step is a function of both the basicity of the leaving group and the 
acidity of the solution. 
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F
igure 4.23: Chemical structures for maleamic acid derivatives 1-9 
 
 
Figure 4.24: Acid-catalyzed hydrolysis for N-alkylmaleamic acids 1–9. 
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Figure 4.25: Mechanistic pathway for the acid-catalyzed hydrolysis of 1–9 and atenolol ProD 1-
ProD 2. INT and TS are tetrahedral intermediate and transition state, respectively. 
Based on the above-mentioned experimental findings , Karaman’s group believes that 
replacing the N-methylamide group in 1–9 with atenolol molecule, as shown for atenolol 
ProD 1 and ProD 2 in ( Figure 2.6) will not have any significant effect on the relative 
rates of these processes, if they proceed in the same mechanism. Therefore, DFT 
calculations of the kinetic and thermodynamic properties for processes 1–9 might fairly 
predict the rates for the chemical intraconversion of atenolol ProD 1 and ProD 2 to their 
parent drug, atenolol. 
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Figure 4.26: Acid-catalyzed hydrolysis for atenolol ProD 1-ProD 2 
 
The DFT calculations for 1–9 and ProD 1–2 that were conducted by Karaman’s 
group confirmed the following findings revealed by Kirby et al. [69, 88]: 
 
2. Two types of conformations in particular were considered: one in which the 
amide carbonyl is syn to the carboxyl group and another in which it is anti. It 
was found that the global minimum structures for 1–9 and ProD 1–2 all 
reside in the syn conformation (Figure 2.7 ). 
3. Both the substituent on the double bond and the reaction medium has a 
profound effect on the reaction rate. 
The substituent effect  
 The closest distance of approach of the carboxylic oxygen and 
the amide carbonyl oxygen in the ground state is less for the 
more reactive compounds. For example, the distance for the 
unsubstituted maleamic acid amide 1 is 3.16 Å whereas for the 
dimethyl substituted derivative 2 is 3.05 Å. 
 The second structural factor that might have a significant 
effect on the reactivity of an acid amide is the angle by which 
the carboxyl group approaches the amide carbonyl carbon. 
The calculated θ values for the reactive derivatives were found 
to be larger than those for the less reactive acid amides 
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 The rates of the reaction for systems having less strained 
intermediates or products are higher than that having more 
strained intermediates or products. 
 
 
Figure 4.27:  representation of acid-catalyzed hydrolysis in Kirby's acid amides 1-9. GM is the 
global minimum structure 
The solvent effect: 
The gas phase DFT calculated barriers revealed that the rate-
limiting step for the hydrolysis of all N-alkyl maleamic acid 
amides studied regardless of the nature of the amine leaving group 
is a tetrahedral formation. Whereas, when the calculations were 
run in a dielectric constant of 78.39 (water), the rate-limiting step 
for the hydrolysis of the acid amides was the dissociation of the 
tetrahedral intermediate.  
4. calculations of the mechanism for the acid-catalyzed hydrolysis demonstrate 
that the process involves (Figure 2.5): 
  A proton transfer from the carboxylic group into the adjacent 
amide carbonyl carbon  
  A nucleophilic attack of the carboxylate anion thus formed onto 
the protonated carbonyl carbon to form a tetrahedral 
intermediate 
  A dissociation of tetrahedral intermediate  to give products  
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4.2.2 Summary 
 
As shown from the previous results, the hydrolysis studies of the atenolol ProD 1 and 
ProD 3 were carried out in aqueous buffer solutions at different pH values (1, 3, 5 and 
7.4, respectively) to evaluate their  fate during  passage through the GIT and after 
absorption and reaching the blood circulation, because the mean fasting stomach pH of 
adult is approximately 1-2 and increases up to 5 following ingestion of food. In addition, 
buffer pH 5 mimics the beginning of the small intestine pathway. Finally, pH 7.4 was 
selected to examine the interconversion of the tested prodrug in blood circulation 
system. 
At 1N HCl atenolol ProD 1 was intraconverted to release the parent drug in 1.66 hour. 
On the other hand, at pH 7.4, the prodrug was entirely stable and no release of the parent 
drug was observed. Since the pKa of the carboxylic group of atenolol ProD 1 is in the 
range of 3-4, it is expected that at pH 5 the anionic form of the prodrug will be dominant 
and the percentage of the free acid form that expected to undergo hydrolysis will be 
relatively low. At 1N HCl and pH 3 most of the prodrug will exist as the free acid form, 
whereas at pH 7.4 most of the prodrug will be in the anionic form. Thus, the difference 
in rates at the different pH buffers.  
It is important to mention that maleic anhydride is particularly considered suitable linker, 
because it is produced in the body in the Kribs’ cycle, so it is nontoxic when released in 
vivo after the prodrug hydrolysis, and it becomes ionized at physiological pH, so it 
contributes to the increased solubility of the prodrug.  
 
Table 4.4: The observed k value and t 1/2 for the intraconverion of atenolol ProD 1 in 1N 
HCl and at pH 3, pH 5 and pH 7.4. 
Medium kobs (hours
−1
) t 1/2 (hours) 
1N HCl 4.161 × 10
−1
 1.66 
Buffer pH 3 1.86 × 10
−1
 3.73 
Buffer pH 5 4.14 × 10
−3
 168 
Buffer pH 7.4 No reaction  No reaction  
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Acid catalyzed hydrolysis of atenolol ProD 2 was found to be readily intraconverted, 
according to structural feature of 2,3-dimethyl maleic moiety it contains two methyl 
groups on the C-C double bond (strained system) which results in a decrease of the 
distance between the two reactive centers (hydroxyl oxygen of the carboxylic group and 
the amide carbonyl carbon). Hence, the hydrolysis of atenolol ProD 2 is very fast. 
 
In the case of atenolol ProD 3 the interatomic distance between the nucleophile (OH) 
and electrophile (C=O) is too high to make the nucleophile attack accessible. Hence, no 
reaction was observed with this prodrug (Table 4.4 ). 
 
Table 4.5 :The observed k value and t 1/2 for the intraconverion of atenolol ProD 3 in 1N 
HCl and at pH 3, pH 5 and pH 7.4. 
Medium kobs (h
-1
) t½ (h) 
1N HCl No reaction No reaction 
Buffer pH3 No reaction No reaction 
Buffer pH 5 No reaction No reaction 
Buffer pH 7.4 No reaction No reaction 
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Conclusions and future directions 
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5.1 Conclusions 
Based on Kirby`s enzyme model (proton transfer in N-alkylmaleamic acids) atenolol 
prodrugs  were  synthesized and their acid-catalyzed hydrolysis reactions demonstrated 
that the rate-limiting step was the breakdown of the tetrahedral intermediate. 
The  experimental value at pH 5 was 168 hours and at pH 7.4 no interconversion was 
observed. The lack of the reaction at the latter pH might be due to the fact that at this pH 
atenolol ProD 1 exists solely in the ionized form (pKa about 3-4). As mentioned before, 
the free acid form is a mandatory requirement for the reaction to proceed. On the other 
hand atenolol ProD 2 was found to be readily intraconverted , but In the case of atenolol 
ProD 3 no reaction was observed . 
5.2 Future directions 
Future strategy to achieve more efficient atenolol prodrugs capable of increasing the 
liquid formulation stability, eliminating atenolol bitterness, and releasing the parent drug 
in a programmable manner is (i) synthesis of atenolol prodrugs having pKa around 6 
(intestine pH) such as atenolol ProD 4; (ii) in vitro kinetic studies of atenolol ProD 4 
will be performed at pH 6.5 (intestine) and pH 7.4 (blood circulation system); and (iii) in 
vivo pharmacokinetic studies will be done in order to determine the bioavailability and 
the duration of action of the tested prodrug. Furthermore, based on the in 
vivo pharmacokinetics characteristics of atenolol ProD 4, new prodrugs may be designed 
and synthesized. 
 
Figure 4.28:  The purposed structure of atenolol ProD 4 
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 الملخص:
هييت كل ييفل  يي  يالميييت لايي  يا ييي  ن يا  ي  يي   نشيي  عبيي عن عيي  عييفي  كل يي   يي   يي     يي   هييي  sgurdorP  
ك مييي   لعل ييي ا ياييي  ي   يالفثييييل  يال و ييي  يا ييي ي     هيييف  sgurdorPيافل اييي  يا ل . ييي . يا ييي ء عييي  لع ييي   
ع  ليييي  خ ييييب  م   ييييب   1952 سيييي    لأ ل عيييي ن  sgurdorP يل يلإخيييي يى  يييي  يالمييييت . ع يييي        ييييف 
ا ب يييفم.   ييين   يييب   يال يييي  عييي   ييي و و يلأ  يييي    يال  فافم ييي  يا  فيييي  يا ييي   ن  عل   ييي  لإسيييل  يم 
  ال يييفي  ك  فافم ييي و ياييي  ي  يا مييي ع   يالييي  كلييي ن   عييي  عشييي و   ييي  ك يييفي   يلأ  يييي  يال ي ييي     sgurdorP
 ع   ن  ق  يسل  ك ب ل   ع   يلأ  ي  يال ي ن  يا مللب   .
عيياخ ي   ييبي  ك يي  ت يلأ  ييي   يلل يي   ع يي  ن ييف علذيييي  ع يي  كل  يي و يا  يي  ى يا  سييف.  .  يي  ياللييف  يال   يي  
.    يييي   ميييي ص يا  يييي   ياف ذي   يييي   يا       يييي   يالذي  يييي  يا  ضيييي    دسييييل  ع   سيييي ا ل يا    يييي   يا  سييييف 
ياليييي  كل ييييفل و      يييي  لايييي  يايييي  ي   sgurdorPيضيييي  ال يييي  ت  سييييل  يع   لا   وبيييي و. هيييي ب يلأسيييي ا ل  ي  يييي  
س سيي   ع يي  يا  ييفن  ايي   يايي  ي  يافليي ل  يلل يي  .شيي   ل.يي    كيي خ  عيي  يلأنييذيت يا  فييذ .  هيي ي يال ييفل يافليي ل 
اييي  ي    sgurdorP هلاكييي   ييي     TFD. . ييي   ع ييي   مييي . و  ssecorp ralucelomartniيا  ييي  ن  ييي   
 عييي   SM-CL RMN-H1، RI-TFسيييل  يم  م يييذن  إ.  ييين كيييت ك ييي  ل     عيسييي  خ   ييي   يلأك فايييفل 
ا يي   كلييإه  لايي   يي  وب يي  . عميي    2/1tهييت  عيسيي  ك فا يي  لايي  يايي  ي  يافليي ل   . يي  ي ع يي  هيي ب يا عيسيي و  ميي     
 فض  ا فس .يا  
سي ع  ع ي  ياليفيا    861 , 37.3 , 66.1هي  )5 Hp  ,3 Hp ,lCH N1 ( يا  ي  ن  ي  t2/1   ني  يي ت  
 ليي  ويي   ك فايي  سيي يل ميي ي   يي   2 DorP  ييت ي يي م  و ك ييفل  عيي  م يي   خيي   . ا مييب  ل  HP  7.4 عيي   يي   
  .و ك فل ي و  ع   يلاطلاق  ات ي  م  3 DorP  ا   
 
